Article Type
Review
Published
This multicentre, retrospective study evaluates the efficacy and safety of risankizumab in a population of psoriatic patients with palmoplantar involvement over a 52-week treatment period.
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.